{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=13", "query": { "intervention": "Blinded (placebo)", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 2208, "total_pages": 221, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Blinded+%28placebo%29&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T17:23:38.609Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04566601", "title": "A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Borderline Personality Disorder" ], "interventions": [ { "name": "BI 1358894", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 390, "start_date": "2020-11-13", "completion_date": "2023-01-25", "has_results": true, "last_update_posted_date": "2024-01-30", "last_synced_at": "2026-10-14T17:23:38.609Z", "location_count": 16, "location_summary": "Anaheim, California • Temecula, California • Upland, California + 13 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Temecula", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566601" }, { "nct_id": "NCT03506633", "title": "Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Peripheral Arterial Disease", "Peripheral Artery Disease" ], "interventions": [ { "name": "MitoQ", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 14, "start_date": "2018-09-05", "completion_date": "2022-01-17", "has_results": true, "last_update_posted_date": "2025-04-01", "last_synced_at": "2026-10-14T17:23:38.609Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03506633" }, { "nct_id": "NCT04642638", "title": "Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Coronavirus Infection", "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)", "COVID-19 Disease" ], "interventions": [ { "name": "INO-4800", "type": "DRUG" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Inovio Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1307, "start_date": "2020-11-30", "completion_date": "2022-09-13", "has_results": true, "last_update_posted_date": "2023-12-20", "last_synced_at": "2026-10-14T17:23:38.609Z", "location_count": 16, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 12 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Coral Gables", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04642638" }, { "nct_id": "NCT01936909", "title": "Interleukin-1 Blockade in Recently Decompensated Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Anakinra (weeks 1-2)", "type": "DRUG" }, { "name": "Anakinra (weeks 3-12)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "21 Years to 130 Years" }, "enrollment_count": 60, "start_date": "2014-02", "completion_date": "2016-09-23", "has_results": true, "last_update_posted_date": "2017-12-22", "last_synced_at": "2026-10-14T17:23:38.609Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01936909" }, { "nct_id": "NCT03827798", "title": "Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hidradenitis Suppurativa" ], "interventions": [ { "name": "CFZ533", "type": "DRUG" }, { "name": "Placebo to CFZ533", "type": "DRUG" }, { "name": "LYS006", "type": "DRUG" }, { "name": "Placebo to LYS006", "type": "DRUG" }, { "name": "MAS825", "type": "DRUG" }, { "name": "Placebo to MAS825", "type": "DRUG" }, { "name": "LOU064 25mg", "type": "DRUG" }, { "name": "LOU064 100mg", "type": "DRUG" }, { "name": "Placebo to LOU064", "type": "DRUG" }, { "name": "VAY736", "type": "DRUG" }, { "name": "Placebo to VAY736", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 248, "start_date": "2019-02-27", "completion_date": "2026-12-11", "has_results": true, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-14T17:23:38.609Z", "location_count": 8, "location_summary": "Clearwater, Florida • Orange Park, Florida • Tampa, Florida + 5 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Orange Park", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03827798" }, { "nct_id": "NCT05964868", "title": "Efficacy of Liposomal Bupivacaine Post Septorhinoplasty", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rhinoplasty", "Pain Management" ], "interventions": [ { "name": "Liposomal Bupivacaine", "type": "DRUG" }, { "name": "0.25% bupivacaine with 1:200,000 epinephrine", "type": "DRUG" }, { "name": "Placebo - Saline solution", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Jessyka Lighthall", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 72, "start_date": "2024-02-05", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-04-03", "last_synced_at": "2026-10-14T17:23:38.609Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05964868" }, { "nct_id": "NCT06690996", "title": "A Study of LY4005130 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "LY4005130", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 110, "start_date": "2024-11-08", "completion_date": "2026-04-28", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-14T17:23:38.609Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06690996" }, { "nct_id": "NCT02079480", "title": "Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Adult Volunteers" ], "interventions": [ { "name": "BMS-986090", "type": "DRUG" }, { "name": "Placebo matching with BMS-986090", "type": "DRUG" }, { "name": "Keyhole limpet hemocyanin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 130, "start_date": "2014-05", "completion_date": "2016-04", "has_results": false, "last_update_posted_date": "2016-05-12", "last_synced_at": "2026-10-14T17:23:38.609Z", "location_count": 2, "location_summary": "Glendale, California • Baltimore, Maryland", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02079480" }, { "nct_id": "NCT05477524", "title": "An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lyme Disease" ], "interventions": [ { "name": "VLA15", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "5 Years", "maximum_age": null, "sex": "ALL", "summary": "5 Years and older" }, "enrollment_count": 12546, "start_date": "2022-08-04", "completion_date": "2026-01-07", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-14T17:23:38.609Z", "location_count": 82, "location_summary": "Essex, Connecticut • Ledyard Center, Connecticut • New London, Connecticut + 67 more", "locations": [ { "city": "Essex", "state": "Connecticut" }, { "city": "Ledyard Center", "state": "Connecticut" }, { "city": "New London", "state": "Connecticut" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Stamford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05477524" }, { "nct_id": "NCT04501978", "title": "ACTIV-3: Therapeutics for Inpatients With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid19" ], "interventions": [ { "name": "LY3819253", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Remdesivir", "type": "BIOLOGICAL" }, { "name": "VIR-7831", "type": "BIOLOGICAL" }, { "name": "BRII-196/BRII-198", "type": "BIOLOGICAL" }, { "name": "AZD7442", "type": "BIOLOGICAL" }, { "name": "MP0420", "type": "DRUG" }, { "name": "PF-07304814", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2753, "start_date": "2020-08-04", "completion_date": "2023-07-14", "has_results": false, "last_update_posted_date": "2023-08-25", "last_synced_at": "2026-10-14T17:23:38.609Z", "location_count": 98, "location_summary": "Tucson, Arizona • Chula Vista, California • Fresno, California + 64 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Mesa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04501978" } ] }